A detailed history of Kazazian Asset Management, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Kazazian Asset Management, LLC holds 7,600 shares of EXEL stock, worth $249,356. This represents 0.19% of its overall portfolio holdings.

Number of Shares
7,600
Holding current value
$249,356
% of portfolio
0.19%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$25.39 - $36.46 $192,964 - $277,096
7,600 New
7,600 $253 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.6B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Kazazian Asset Management, LLC Portfolio

Follow Kazazian Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kazazian Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kazazian Asset Management, LLC with notifications on news.